296 related articles for article (PubMed ID: 18159923)
1. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T
Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673
[TBL] [Abstract][Full Text] [Related]
3. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
[TBL] [Abstract][Full Text] [Related]
4. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
5. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
Quan ML; Han Q; Fevig JM; Lam PY; Bai S; Knabb RM; Luettgen JM; Wong PC; Wexler RR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1795-8. PubMed ID: 16434195
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
Ueno H; Katoh S; Yokota K; Hoshi J; Hayashi M; Uchida I; Aisaka K; Hase Y; Cho H
Bioorg Med Chem Lett; 2004 Aug; 14(16):4281-6. PubMed ID: 15261287
[TBL] [Abstract][Full Text] [Related]
7. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
[TBL] [Abstract][Full Text] [Related]
8. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.
Nazaré M; Will DW; Matter H; Schreuder H; Ritter K; Urmann M; Essrich M; Bauer A; Wagner M; Czech J; Lorenz M; Laux V; Wehner V
J Med Chem; 2005 Jul; 48(14):4511-25. PubMed ID: 15999990
[TBL] [Abstract][Full Text] [Related]
9. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Czech J; Lorenz M; Laux V; Wehner V
Bioorg Med Chem Lett; 2004 Aug; 14(16):4197-201. PubMed ID: 15261269
[TBL] [Abstract][Full Text] [Related]
10. Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.
Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Dudda A; Czech J; Lorenz M; Laux V; Wehner V
Bioorg Med Chem Lett; 2004 Aug; 14(16):4191-5. PubMed ID: 15261268
[TBL] [Abstract][Full Text] [Related]
11. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
[TBL] [Abstract][Full Text] [Related]
12. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.
Kochanny MJ; Adler M; Ewing J; Griedel BD; Ho E; Karanjawala R; Lee W; Lentz D; Liang AM; Morrissey MM; Phillips GB; Post J; Sacchi KL; Sakata ST; Subramanyam B; Vergona R; Walters J; White KA; Whitlow M; Ye B; Zhao Z; Shaw KJ
Bioorg Med Chem; 2007 Mar; 15(5):2127-46. PubMed ID: 17227710
[TBL] [Abstract][Full Text] [Related]
13. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.
Li YL; Fevig JM; Cacciola J; Buriak J; Rossi KA; Jona J; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Oct; 16(19):5176-82. PubMed ID: 16870435
[TBL] [Abstract][Full Text] [Related]
14. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
15. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.
Maignan S; Guilloteau JP; Choi-Sledeski YM; Becker MR; Ewing WR; Pauls HW; Spada AP; Mikol V
J Med Chem; 2003 Feb; 46(5):685-90. PubMed ID: 12593649
[TBL] [Abstract][Full Text] [Related]
16. Design of benzamidine-type inhibitors of factor Xa.
Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
[TBL] [Abstract][Full Text] [Related]
17. The discovery of glycine and related amino acid-based factor Xa inhibitors.
Kohrt JT; Filipski KJ; Cody WL; Bigge CF; La F; Welch K; Dahring T; Bryant JW; Leonard D; Bolton G; Narasimhan L; Zhang E; Peterson JT; Haarer S; Sahasrabudhe V; Janiczek N; Desiraju S; Hena M; Fiakpui C; Saraswat N; Sharma R; Sun S; Maiti SN; Leadley R; Edmunds JJ
Bioorg Med Chem; 2006 Jul; 14(13):4379-92. PubMed ID: 16529937
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
Pruitt JR; Pinto DJ; Galemmo RA; Alexander RS; Rossi KA; Wells BL; Drummond S; Bostrom LL; Burdick D; Bruckner R; Chen H; Smallwood A; Wong PC; Wright MR; Bai S; Luettgen JM; Knabb RM; Lam PY; Wexler RR
J Med Chem; 2003 Dec; 46(25):5298-315. PubMed ID: 14640539
[TBL] [Abstract][Full Text] [Related]
19. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
